Adam Gehring is currently the Scientific Director of the Schwartz Reisman Liver Research Centre and Senior Scientist at the Toronto Center for Liver Disease at the University Health Network and Associate Professor in the Department of Immunology at the University of Toronto. He runs a translational, human HBV immunology research lab focused on liver pathogenesis and immunotherapy. His primary interest lies in defining the mechanisms responsible for HBV clearance and liver inflammation using functional and transcriptomic approaches in liver biopsies collected as part of Phase 1 – 3 clinical trials.